✦ LIBER ✦

Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells

✍ Scribed by Rena G. Lapidus; Carol W. Tiffany; John T. Isaacs; Barbara S. Slusher

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 202 KB
Volume: 45
Category: Article
ISSN: 0270-4137
DOI: 10.1002/1097-0045(20001201)45:4<350::aid-pros10>3.0.co;2-u

No coin nor oath required. For personal study only.

✦ Synopsis

Background:

Prostate-specific membrane antigen (psma) is a glutamate carboxypeptidase that cleaves terminal carboxy glutamates from both the neuronal dipeptide n-acetylaspartylglutamate (naag) and gamma-linked folate polyglutamate. the prostate enzyme has activity in both the membrane and cytosolic fractions termed psma and psma', respectively.

Methods:

Using a naag hydrolytic radioenzymatic assay, we quantitated the enzymatic activity of psma and psma' in normal, benign prostatic hyperplasia (bph), and prostate cancer (pc) tissues from radical prostatectomies. psma enzyme activity was evaluated in each tissue type and expressed per milligram protein and epithelial cell content.

Results:

Psma and psma' enzyme activities were significantly elevated in prostate cancer when compared to normal prostate tissue and bph. ratios of psma to psma' were also decreased in bph as compared to cancerous and normal tissue.

Conclusions:

Prostate carcinogenesis is associated with an elevation in psma and psma' enzyme activity. in contrast, no such enhancement in psma activity is observed with benign neoplastic changes in bph. thus, the enhancement observed in prostate cancer is not simply related to a generalized prostatic hyperplasia, but is specific to its malignancy.

📜 SIMILAR VOLUMES

Report of immune monitoring of prostate

Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)

✍ Salgaller, Michael L.; Lodge, Patricia A.; McLean, Joanne G.; Tjoa, Ben A.; Loft 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 336 KB 👁 2 views

## BACKGROUND. In this paper we describe our program for the immune monitoring of phase II participants given dendritic cell (DC)/prostate-specific membrane antigen (PSMA)-based immunotherapy, and we also present some initial findings. METHODS. Phase II subjects received six administrations of aut

Infusion of dendritic cells pulsed with

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

✍ Murphy, G.P.; Tjoa, B.A.; Simmons, S.J.; Jarisch, J.; Bowes, V.A.; Ragde, H.; Ro 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB 👁 1 views

## Background: A phase ii trial was conducted to assess the efficacy of infusions of dendritic cells (dc) and two hla-a2-specific psma peptides (psm-p1 and -p2). this report describes thirty three subjects with hormone-refractory metastatic prostate cancer without prior vaccine therapy history who

Establishing human prostate cancer cell

Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines

✍ Tony T. Wu; Robert A. Sikes; Quanjun Cui; George N. Thalmann; Chinghai Kao; Cher 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 497 KB 👁 2 views

LNCaP lineage-derived human prostate cancer cell lines C4-2 and C4-2B 4 acquire androgen independence and osseous metastatic potential in vivo. Using C4-2 and C4-2B 4 the goals of the current investigation were 1) to establish an ideal bone xenograft model for prostate cancer cells in intact athymic

Elevation of serum levels of urokinase-t

Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer

✍ Miyake, Hideaki; Hara, Isao; Yamanaka, Kazuki; Gohji, Kazuo; Arakawa, Soichi; Ka 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 1 views

BACKGROUND. Several investigators have revealed that urokinase-type plasminogen activator (uPA) and its receptor (uPAR) are overexpressed in serum as well as in tumor tissues in patients with various types of cancer. In this study, we examined whether the serum levels of uPA and uPAR could be used a